Myriad Genetics Stock Income Statements

Myriad Genetics Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Myriad Genetics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2004-12-31	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31

revenue	213,100,000	195,900,000																																																					73,668,000	102,374,000	100,440,000	91,858,000
yoy
qoq	8.78%																																																						-28.04%	1.93%	9.34%
cost of revenue	61,300,000	61,700,000																																																					8,547,750	11,133,000	12,046,000	11,011,000
gross profit	151,800,000	134,200,000
yoy
qoq	13.11%
gross margin %	71.23%	68.50%																																																					0%	0%	0%	0%
costs and expenses:
research and development expense	25,600,000	27,500,000	32,200,000	28,500,000	27,100,000	24,900,000	21,000,000	24,000,000	21,200,000	22,500,000	23,400,000	20,500,000	20,300,000	21,200,000	20,500,000	18,800,000	19,500,000	23,100,000	17,600,000	17,400,000	19,700,000	18,800,000	21,300,000	20,900,000	21,500,000	22,400,000	21,100,000	17,700,000	18,500,000	16,800,000	17,800,000	18,800,000	17,600,000	18,600,000	19,400,000	19,500,000	17,200,000	16,700,000	17,200,000	18,712,000	16,673,000	17,504,000	22,612,000	20,187,000	13,397,000	17,090,000	16,803,000	14,581,000	13,618,000	14,107,000	11,400,000	12,143,000	11,753,000	8,505,000	9,231,000	6,667,000	6,092,000	5,762,000	5,253,000	5,885,000	5,059,000	5,676,000	-37,036,000	17,850,000	19,952,000	17,149,000	55,225,000	31,161,000	27,306,000	26,025,000	26,175,000	23,418,000	24,764,000	26,352,000	24,294,000	21,967,000	19,030,000	18,466,000	14,546,000	12,390,000	11,558,000	12,974,000	13,372,000	11,053,000	12,218,000
sales and marketing expense	71,900,000	69,200,000
general and administrative expense	66,800,000	66,500,000
goodwill and long-lived asset impairment charges	316,700,000		43,000,000	2,200,000	11,600,000						6,200,000			10,700,000			1,800,000
total operating expenses	481,000,000	163,200,000
operating income	-329,200,000	-29,000,000	-39,000,000	-20,000,000	-36,500,000	-27,900,000	-31,400,000	-60,100,000	-113,700,000	-52,200,000	-52,200,000	-45,000,000	-17,800,000	-25,600,000	-43,100,000	-79,900,000	-20,800,000	-46,700,000	-39,600,000	-68,300,000	-133,700,000	-8,800,000	-20,900,000	-5,600,000	5,900,000	6,100,000	1,200,000	9,700,000	17,000,000	4,400,000	87,400,000	17,000,000	12,900,000	13,200,000	6,200,000	35,600,000	42,600,000	45,200,000	43,300,000	36,198,000	35,740,000	36,342,000	25,920,000	53,254,000	55,287,000	82,999,000	82,904,000	65,916,000	57,918,000	55,586,000	48,582,000	47,286,000	46,096,000	41,472,000	41,777,000	41,824,000	38,586,000	35,591,000	37,615,000	33,225,000	34,522,000	29,712,000	73,073,000	22,311,000	17,766,000	13,312,000	66,214,000	-7,816,000	-8,736,000	-11,582,000	-12,266,000	-9,092,000	-11,369,000	-15,000,000	-13,981,000	-11,954,000	-9,600,000	-10,053,000		-11,164,000	-10,381,000	-10,168,000
yoy	801.92%	3.94%	24.20%	-66.72%	-67.90%	-46.55%	-39.85%	33.56%	538.76%	103.91%	21.11%	-43.68%	-14.42%	-45.18%	8.84%	16.98%	-84.44%	430.68%	89.47%	1119.64%	-2366.10%	-244.26%	-1841.67%	-157.73%	-65.29%	38.64%	-98.63%	-42.94%	31.78%	-66.67%	1309.68%	-52.25%	-69.72%	-70.80%	-85.68%	-1.65%	19.19%	24.37%	67.05%	-32.03%	-35.36%	-56.21%	-68.73%	-19.21%	-4.54%	49.32%	70.65%	39.40%	25.65%	34.03%	16.29%	13.06%	19.46%	16.52%	11.06%	25.88%	11.77%	19.79%	-48.52%	48.92%	94.31%	123.20%	10.36%	-385.45%	-303.37%	-214.94%	-639.82%	-14.03%	-23.16%	-22.79%	-12.27%	-23.94%	18.43%	49.21%		7.08%	-7.52%	-1.13%
qoq	1035.17%	-25.64%	95.00%	-45.21%	30.82%	-11.15%	-47.75%	-47.14%	117.82%	0.00%	16.00%	152.81%	-30.47%	-40.60%	-46.06%	284.13%	-55.46%	17.93%	-42.02%	-48.92%	1419.32%	-57.89%	273.21%	-194.92%	-3.28%	408.33%	-87.63%	-42.94%	286.36%	-94.97%	414.12%	31.78%	-2.27%	112.90%	-82.58%	-16.43%	-5.75%	4.39%	19.62%	1.28%	-1.66%	40.21%	-51.33%	-3.68%	-33.39%	0.11%	25.77%	13.81%	4.20%	14.42%	2.74%	2.58%	11.15%	-0.73%	-0.11%	8.39%	8.42%	-5.38%	13.21%	-3.76%	16.19%	-59.34%	227.52%	25.58%	33.46%	-79.90%	-947.16%	-10.53%	-24.57%	-5.58%	34.91%	-20.03%	-24.21%	7.29%	16.96%	24.52%	-4.51%			7.54%	2.09%
operating margin %	-154.48%	-14.80%																																																					56.71%	40.85%	38.42%	38.75%
other income:
interest income	200,000	300,000	300,000	400,000	400,000	600,000	700,000	600,000	500,000	700,000	1,000,000	1,100,000	400,000	100,000	100,000	200,000	200,000	200,000	400,000	500,000	800,000	800,000	900,000	900,000	700,000	900,000	700,000	600,000	500,000	400,000	400,000	300,000	300,000	300,000	300,000	400,000	300,000	100,000	100,000	135,000	124,000	85,000	55,000	207,000	2,498,000	1,330,000	1,362,000	1,310,000	1,434,000	1,385,000	1,368,000	1,394,000	1,379,000	473,000	410,000	547,000	548,000	721,000	984,000	1,232,000	1,531,000	1,913,000	2,661,000	2,946,000	3,437,000	3,434,000	2,935,000	3,250,000	3,667,000	3,857,000	3,814,000	3,123,000	2,573,000	2,602,000	2,545,000	2,407,000	1,649,000	811,000	687,000	473,000	527,000	569,000	632,000	701,000	725,000
interest expense	-1,500,000	-800,000	-700,000	-800,000	-800,000	-500,000	-900,000	-1,000,000	-500,000	-500,000	-900,000	-800,000	-600,000	-900,000	-500,000	-1,100,000	-2,000,000	-3,000,000	-2,900,000	-3,100,000	-2,300,000	-2,500,000	-2,900,000	-3,200,000	-3,200,000	-3,400,000	-2,200,000	-1,000,000	-500,000	-700,000	-900,000	-1,200,000	-1,500,000	-2,600,000
other	-100,000	100,000	300,000	-800,000	-300,000	1,900,000	-700,000	-700,000	-2,400,000	-600,000		500,000	100,000			120,600,000	18,800,000	-100,000	-1,600,000	12,400,000	4,100,000	-900,000	600,000	200,000	-100,000		1,100,000	900,000	-500,000	-400,000	-300,000	-100,000	1,500,000	1,200,000	-2,500,000		200,000	-300,000	100,000				-98,000	-908,000	-442,000	-185,000	-439,000	1,000	-111,000	14,000	-128,000	-208,000	6,000	-140,000	-80,000	-59,000	-80,000	-134,000	5,000	23,000	286,000	-215,000	-455,000	-33,000		-2,005,000	-3,000,000	-65,000	2,000	-274,000	648,000	32,000		-27,000	12,000	-24,000	-1,000			-5,000		-10,000	3,000	1,000
total other income	-1,400,000	-400,000	25,000	-1,200,000	-700,000	2,000,000	-900,000	-1,100,000	-2,400,000	-400,000	-25,000	800,000	-100,000	-800,000	-400,000	119,700,000	17,000,000	-2,900,000	-4,100,000																					345,500	-174,000	1,598,000	-43,000	1,031,000	2,056,000	1,145,000	923,000	990,750	1,323,000	1,399,000	1,240,000	1,186,000	1,385,000	333,000	330,000	488,000	468,000	587,000	989,000	1,255,000	1,817,000	1,698,000	2,206,000	2,913,000	3,437,000	1,429,000
income before income tax	-330,600,000	-29,400,000	-39,100,000	-21,200,000	-37,200,000	-25,900,000	-32,300,000	-61,200,000	-116,100,000	-52,600,000	-52,100,000	-44,200,000	-17,900,000	-26,400,000	-43,500,000	39,800,000	-3,800,000	-49,600,000	-43,700,000	-58,500,000	-131,100,000	-11,400,000	-22,300,000	1,925,000	3,300,000	3,600,000	800,000	10,200,000	16,500,000	3,700,000	86,600,000	18,800,000	8,000,000	12,100,000	4,000,000	37,200,000	43,100,000	45,000,000	43,500,000
income tax benefit	-100,000						-1,100,000	100,000		2,100,000	-9,800,000	-9,100,000	-3,800,000	-5,900,000	-35,900,000	15,200,000	900,000	-10,100,000	-28,500,000	-3,000,000	-15,900,000	-3,100,000	-1,700,000																																				-14,646,000	1,229,000			48,250	-94,000
net income	-330,500,000	-100,000	-42,500,000	-22,100,000	-36,700,000	-26,000,000	-31,200,000	-61,300,000	-116,100,000	-54,700,000	-42,300,000	-35,100,000	-14,100,000	-20,500,000	-7,600,000	24,600,000	-4,700,000	-39,500,000	-15,200,000	-55,500,000	-115,200,000	-8,300,000	-20,600,000	-4,300,000	6,900,000	2,600,000	-800,000	6,500,000	11,300,000	32,100,000	81,000,000	12,700,000	4,200,000	5,900,000	-1,200,000	35,700,000	32,600,000	30,300,000	26,600,000	18,712,000	21,475,000	24,031,000	15,982,000	33,632,000	36,770,000	50,360,000	55,465,000	44,074,000	37,892,000	35,036,000	30,136,000	29,142,000	29,615,000	25,099,000	26,040,000	27,940,000	24,191,000	22,538,000	53,250,000	33,251,000	35,359,000	30,442,000	23,640,000	25,318,000	21,203,000	14,454,000	65,541,000	-4,631,000	-5,067,000	-7,999,000	-7,804,000	-5,937,000	-8,796,000	-12,425,000	-11,424,000	-9,571,000	-7,952,000	-9,242,000	-10,048,000	-10,696,000	-9,854,000	-9,609,000	-7,081,000	-5,534,000	-6,894,000
yoy	800.54%	-99.62%	36.22%	-63.95%	-68.39%	-52.47%	-26.24%	74.64%	723.40%	166.83%	456.58%	-242.68%	200.00%	-48.10%	-50.00%	-144.32%	-95.92%	375.90%	-26.21%	1190.70%	-1769.57%	-419.23%	2475.00%	-166.15%	-38.94%	-91.90%	-100.99%	-48.82%	169.05%	444.07%	-6850.00%	-64.43%	-87.12%	-80.53%	-104.51%	90.79%	51.80%	26.09%	66.44%	-44.36%	-41.60%	-52.28%	-71.19%	-23.69%	-2.96%	43.74%	84.05%	51.24%	27.95%	39.59%	15.73%	4.30%	22.42%	11.36%	-51.10%	-15.97%	-31.58%	-25.96%	125.25%	31.33%	66.76%	110.61%	-63.93%	-646.71%	-518.45%	-280.70%	-939.84%	-22.00%	-42.39%	-35.62%	-31.69%	-37.97%	10.61%	34.44%	13.69%	-10.52%	-19.30%	-3.82%	41.90%	93.28%	42.94%
qoq	330400.00%	-99.76%	92.31%	-39.78%	41.15%	-16.67%	-49.10%	-47.20%	112.25%	29.31%	20.51%	148.94%	-31.22%	169.74%	-130.89%	-623.40%	-88.10%	159.87%	-72.61%	-51.82%	1287.95%	-59.71%	379.07%	-162.32%	165.38%	-425.00%	-112.31%	-42.48%	-64.80%	-60.37%	537.80%	202.38%	-28.81%	-591.67%	-103.36%	9.51%	7.59%	13.91%	42.15%	-12.87%	-10.64%	50.36%	-52.48%	-8.53%	-26.99%	-9.20%	25.85%	16.31%	8.15%	16.26%	3.41%	-1.60%	17.99%	-3.61%	-6.80%	15.50%	7.33%	-57.68%	60.15%	-5.96%	16.15%	28.77%	-6.63%	19.41%	46.69%	-77.95%	-1515.27%	-8.60%	-36.65%	2.50%	31.45%	-32.50%	-29.21%	8.76%	19.36%	20.36%	-13.96%	-8.02%	-6.06%	8.54%	2.55%	35.70%	27.95%	-19.73%
net income margin %	-155.09%	-0.05%																																																					35.35%	27.29%	24.09%	24.54%
net income per share
basic and diluted	-3.57		-0.47	-0.24	-0.41	-0.29	-0.34	-0.75	-1.42	-0.67			-0.18	-0.26			-0.06	-0.52	-0.2
weighted-average shares outstanding:
basic and diluted	92.5	91.4	90.6	90.9	90.6	89.9	82.8	81.9	81.7	81.3	80.6		80.4	80.1			77.2	76	74.7
income tax (benefit) expense		-29,300,000			-500,000
testing revenue			156,750,000	213,300,000	211,500,000	202,200,000	196,600,000	191,900,000	183,500,000	181,200,000
cost of testing revenue			48,125,000	63,500,000	64,400,000	64,600,000	61,600,000	57,600,000	57,800,000	59,200,000
selling, general, and administrative expense			106,000,000	139,100,000	144,900,000	140,600,000	144,400,000	136,100,000	140,700,000	151,700,000	146,500,000	130,500,000	127,100,000	110,600,000	77,300,000	180,200,000	134,800,000	145,500,000	124,100,000	107,400,000	132,900,000	135,600,000	135,500,000	149,800,000	140,600,000	135,200,000	129,900,000	121,600,000	115,100,000	115,400,000	115,200,000	122,100,000	122,100,000	120,300,000	111,900,000	91,300,000	90,500,000	90,800,000	86,500,000	96,585,000	91,279,000	92,695,000	85,440,000	84,345,000	87,631,000	77,840,000	77,279,000	71,545,000	64,602,000	59,563,000	56,128,000	56,584,000	54,700,000	46,114,000	43,881,000	42,750,000	43,716,000	39,494,000	39,798,000	40,840,000	42,104,000	38,672,000	33,792,000	36,094,000	35,598,000	33,399,000	36,366,000	30,157,000	30,482,000	26,488,000
legal settlements
total costs and expenses			177,875,000	233,300,000	248,000,000	230,100,000	228,000,000	252,000,000	297,200,000	233,400,000	230,000,000	201,400,000	197,100,000	190,500,000	203,900,000	247,200,000	210,200,000	219,800,000	184,800,000	161,500,000	297,700,000	203,900,000	207,200,000	221,000,000	210,700,000	210,700,000	201,100,000	185,200,000	176,500,000	189,600,000	102,800,000	183,500,000	184,000,000	183,300,000	171,300,000	150,800,000	147,900,000	148,100,000	140,200,000	153,686,000	144,245,000	148,051,000	142,917,000	135,512,000	127,637,000	121,061,000	119,563,000	108,199,000	98,554,000	93,554,000	84,855,000	85,679,000	83,681,000	68,980,000	65,635,000	60,550,000	61,854,000	56,267,000	56,313,000	57,605,000	58,246,000	55,410,000	7,941,000	65,176,000	66,610,000	60,338,000	100,642,000	69,581,000	65,478,000	59,848,000	57,744,000	50,062,000	48,504,000	48,543,000	46,006,000	41,763,000	36,930,000	35,167,000	30,315,000	24,920,000	24,529,000	23,840,000	23,378,000	22,199,000	24,508,000
income tax expense			100,000	900,000		100,000
legal charges pending settlement							27,950,000	34,300,000	77,500,000
revenues:
molecular diagnostic testing											125,150,000	156,400,000	179,300,000	164,900,000	160,800,000	167,300,000	178,700,000	159,600,000	135,700,000	83,300,000	150,500,000	181,100,000	172,000,000	196,900,000	200,500,000	203,000,000	189,000,000	181,700,000	179,700,000	179,200,000	178,800,000	187,900,000	185,200,000	183,900,000	165,100,000	173,700,000	177,400,000	182,600,000	171,900,000	178,866,000	172,978,000	179,149,000	164,507,000	182,863,000	176,191,000	196,158,000	192,987,000	166,088,000	148,384,000	140,651,000	127,268,000	127,499,000	123,312,000	103,969,000
pharmaceutical and clinical services																	10,700,000	13,500,000	9,500,000	9,900,000	13,500,000	14,000,000	14,300,000	18,500,000	16,100,000	13,800,000	13,300,000	13,200,000	13,800,000	14,800,000	11,400,000	12,600,000	11,700,000	12,600,000	12,400,000	12,700,000	13,100,000	10,700,000	11,600,000	11,018,000	7,007,000	5,244,000	4,330,000
total revenue											177,800,000	156,400,000	179,300,000	164,900,000	160,800,000	167,300,000	189,400,000	173,100,000	145,200,000	93,200,000	164,000,000	195,100,000	186,300,000	215,400,000	216,600,000	216,800,000	202,300,000	194,900,000	193,500,000	194,000,000	190,200,000	200,500,000	196,900,000	196,500,000	177,500,000	186,400,000	190,500,000	193,300,000	183,500,000	189,884,000	179,985,000	184,393,000	168,837,000	188,766,000	182,924,000	204,060,000	202,467,000	174,115,000	156,472,000	149,140,000	133,437,000	132,965,000	129,777,000	110,452,000									61,378,250	87,487,000	84,376,000	73,650,000	166,856,000	61,765,000	56,742,000	48,266,000
cost of molecular diagnostic testing											37,025,000	50,400,000	49,700,000	48,000,000	45,800,000	47,800,000	48,000,000	44,100,000	39,900,000	32,200,000	43,100,000	41,000,000	41,200,000	41,600,000	40,300,000	44,000,000	42,300,000	38,000,000	36,800,000	37,700,000	36,200,000	35,700,000	37,900,000	37,400,000	34,300,000	34,200,000	33,600,000	34,100,000	30,900,000	31,941,000	33,011,000	35,050,000	32,797,000	28,298,000	23,648,000	22,755,000	21,439,000	18,416,000	16,462,000	15,566,000	13,932,000	13,872,000	13,465,000	11,300,000
cost of pharmaceutical and clinical services																	5,700,000	6,200,000	4,300,000	4,500,000	7,000,000	8,600,000	8,500,000	9,000,000	8,300,000	8,100,000	7,400,000	7,800,000	7,300,000	6,700,000	6,800,000	6,900,000	6,400,000	7,000,000	5,700,000	5,800,000	6,600,000	6,500,000	5,600,000	6,448,000	3,282,000	2,802,000	2,068,000
net income attributable to non-controlling interest																								-100,000			-100,000		-100,000		-100,000	-100,000
net income attributable to myriad genetics, inc. stockholders											-42,300,000	-35,100,000	-14,100,000	-20,500,000	-7,600,000	24,600,000	-4,700,000	-39,500,000	-15,200,000	-55,400,000	-115,200,000	-8,300,000	-20,600,000	-4,200,000	6,900,000	2,600,000	-700,000	6,500,000	11,400,000	32,100,000	81,100,000	12,800,000	4,200,000	5,900,000	-1,200,000
net income per share
basic											-0.218	-0.43			-0.063	0.31
diluted											-0.218	-0.43			-0.063	0.3
weighted-average shares outstanding:
basic												80.7			78	78.8				74.3	74.5	74.4	73.7	73.5	73.3	74.2	73	69.4	69.8	69.3	68.6	68.3	68.1	68.2	68.8	70	70.9	70.5	68.7	71.3	70,696	72,467	72,763	75,728	73,821	75,070	79,575	80,948	80,375	81,692	81,572	84,608	84,403	85,241	89,794,000	88,206	91,528	93,263	96,338,000	96,853,000	96,270,000	95,970,000	93,492,000	94,327	46,592	45,398	44,189
diluted												80.7			78	81.5				74.3	74.5	74.4	73.7	76	74.9	76.5	73	72	72.4	71.9	70.4	68.8	68.3	68.3	68.8	73.4	73.5	73.8	72.1	74.5	73,870	75,401	76,086	78,182	76,374	76,825	81,798	83,327	82,434	84,240	83,914	86,465	86,462	87,037	91,704,000	90,127	93,647	94,734	99,152,000	99,674,000	99,426,000	99,492,000	98,573,000	99,594	48,858	48,309	46,704
change in the fair value of contingent consideration															425,000	400,000	400,000	900,000	-1,100,000		-3,400,000	-100,000	700,000	-300,000		1,000,000	400,000	100,000	-1,200,000	13,000,000	-73,200,000	2,800,000	-5,200,000
goodwill and intangible asset impairment charges																					98,400,000
total other income:																				9,800,000	2,600,000	-2,600,000	-1,400,000	-2,100,000	-2,600,000	-2,500,000	-400,000	500,000	-500,000	-700,000	-800,000	1,800,000	-4,900,000	-1,100,000	-2,200,000	1,600,000	500,000	-200,000	200,000
earnings per share:
basic																				-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.04	-0.01	0.09	0.16	0.46	1.18	0.19	0.06	0.09	-0.02	0.51	0.46	0.43	0.39	0.27	0.3	0.33	0.22	0.46	0.5	0.67	0.7	0.55	0.47	0.43	0.37	0.35	0.35	0.29	0.205	0.32	0.26	0.24					0.165	0.27	0.46	0.32
diluted																				-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.03	-0.01	0.08	0.16	0.45	1.15	0.19	0.06	0.09	-0.02	0.49	0.44	0.41	0.37	0.26	0.29	0.32	0.21	0.43	0.48	0.66	0.68	0.54	0.46	0.42	0.36	0.34	0.34	0.29	0.2	0.31	0.26	0.24					0.155	0.25	0.43	0.3
income tax provision																								-250,000	-3,600,000	1,000,000	1,600,000	3,700,000	5,200,000	-28,400,000	5,600,000	6,100,000	3,800,000	6,200,000	5,200,000	1,500,000	10,500,000	14,700,000	16,900,000	16,804,000	14,091,000	13,909,000	9,895,000	18,921,000	20,573,000	33,784,000	28,362,000	23,153,000	21,349,000	21,949,000	19,686,000	13,264,750	17,866,000	16,706,000	10,718,500	14,372,000	14,863,000	13,640,000			980,000	968,000				287,000
other income																																								279,250	-298,000	1,513,000
income before income taxes																																								24,846,000	35,566,000	37,940,000	25,877,000	52,553,000	57,343,000	84,144,000	83,827,000	67,227,000	59,241,000	56,985,000	49,822,000	48,472,000	47,481,000	41,805,000	29,386,000	42,312,000	39,054,000	36,178,000
weighted-average shares outstanding
basic												80.7			78	78.8				74.3	74.5	74.4	73.7	73.5	73.3	74.2	73	69.4	69.8	69.3	68.6	68.3	68.1	68.2	68.8	70	70.9	70.5	68.7	71.3	70,696	72,467	72,763	75,728	73,821	75,070	79,575	80,948	80,375	81,692	81,572	84,608	84,403	85,241	89,794,000	88,206	91,528	93,263	96,338,000	96,853,000	96,270,000	95,970,000	93,492,000	94,327	46,592	45,398	44,189
diluted												80.7			78	81.5				74.3	74.5	74.4	73.7	76	74.9	76.5	73	72	72.4	71.9	70.4	68.8	68.3	68.3	68.8	73.4	73.5	73.8	72.1	74.5	73,870	75,401	76,086	78,182	76,374	76,825	81,798	83,327	82,434	84,240	83,914	86,465	86,462	87,037	91,704,000	90,127	93,647	94,734	99,152,000	99,674,000	99,426,000	99,492,000	98,573,000	99,594	48,858	48,309	46,704
comprehensive income:
unrealized gain on available-for-sale securities, net of tax																																								-70.5	-6	-145	-132	27	45	253	-285	-525	259	-70	83
change in foreign currency translation adjustment, net of tax																																								-1,420.75	-3,293	-1,669	-721	-1,421	-672	-112	-504	561	-497	-280	208
comprehensive income																																								13,880.75	18,176	22,217	15,129	32,238	36,143	50,501	54,676	44,110	37,654	34,686	30,427
companion diagnostic services																																												6,028,750	6,733,000	7,902,000	9,480,000	8,027,000	8,088,000	8,489,000	6,169,000	5,466,000	6,465,000	6,483,000
cost of companion diagnostic services																																												2,594,750	2,961,000	3,376,000	4,042,000	3,657,000	3,872,000	4,318,000	3,395,000	3,080,000	3,763,000	3,061,000
molecular diagnostic revenue																																																											67,180,000	90,830,000	92,768,000	85,122,000	86,078,000	86,531,000	83,952,000	69,965,000	64,679,000	59,023,000	53,097,000	46,056,000	42,268,000	37,991,000	34,175,000	30,851,000
molecular diagnostic cost of revenue																																																											8,256,000	10,880,000	11,083,000	11,062,000	11,185,000	11,232,000	11,060,000	9,790,000	9,051,000	8,263,000	7,690,000	7,335,000	7,602,000	7,577,000	7,529,000	8,105,000
income from continuing operations before income taxes																																																											38,604,000	34,480,000	36,339,000	31,410,000
income from continuing operations																																																											53,250,000	33,251,000	35,359,000	30,442,000
discontinued operations
income from discontinued operations
earnings per basic share:
continuing operations																																																											550	340	370	320
earnings per basic share																																																											550	340	370	320
earnings per diluted share:
earnings per diluted share																																																											540	330	360	310
revenue:
research and other revenue																																																															1,266,000	956,000	424,000	3,685,000	2,177,000	2,742,000	3,645,000
income before taxes																																																															15,292,000	25,224,000	21,203,000	14,741,000														-10,696,000	-9,854,000	-9,609,000
earnings per share
basic																				-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.04	-0.01	0.09	0.16	0.46	1.18	0.19	0.06	0.09	-0.02	0.51	0.46	0.43	0.39	0.27	0.3	0.33	0.22	0.46	0.5	0.67	0.7	0.55	0.47	0.43	0.37	0.35	0.35	0.29	0.205	0.32	0.26	0.24					0.165	0.27	0.46	0.32
diluted																				-0.75	-1.55	-0.11	-0.28	-0.06	0.09	0.03	-0.01	0.08	0.16	0.45	1.15	0.19	0.06	0.09	-0.02	0.49	0.44	0.41	0.37	0.26	0.29	0.32	0.21	0.43	0.48	0.66	0.68	0.54	0.46	0.42	0.36	0.34	0.34	0.29	0.2	0.31	0.26	0.24					0.155	0.25	0.43	0.3
basic and diluted loss per share																																																																			-0.1	-0.1	-0.11	-0.18	-0.168	-0.14	-0.22	-0.31	-0.19	-0.24	-0.22	-0.3	-0.33	-0.39	-0.36	-0.35	-0.175	-0.2	-0.27
basic and diluted weighted-average shares outstanding																																																																				44,448	44,094	43,568	41,055,000	41,503	39,808	39,700	36,278,000	39,232	35,547	30,886	30,682	27,148	27,109	27,087	25,730,000	27,012	25,081
research revenue																																																																						2,210,000	3,210,000	2,979,000	2,960,000	2,692,000	3,192,000	2,942,000	3,938,000	3,585,000	2,104,000	1,909,000	2,773,000	5,079,000	5,970,000	6,432,000	8,406,000
total revenues																																																																							27,912,000	40,970,000	37,135,000	33,543,000	32,025,000	29,809,000	27,330,000	25,114,000	19,639,000	13,756,000	14,148,000	13,672,000	15,704,000	16,088,000	17,019,000
selling, general and administrative expense																																																																							12,341,250	19,067,000	16,211,000	14,086,000	8,704,500	12,291,000	11,628,000	10,898,000	10,638,000	8,821,000	9,523,000	8,108,000	6,198,750	7,785,000	9,295,000
predictive medicine revenue																																																																											28,833,000	26,867,000	23,392,000	21,529,000	17,535,000	11,699,000	10,446,000	8,064,000	9,354,000	9,314,000	8,151,000
predictive medicine cost of revenue																																																																											8,063,000	7,505,000	6,272,000	5,803,000	5,131,000	3,709,000	3,448,000	2,758,000	3,276,000	3,361,000	2,995,000
related party research revenue																																																																																148,000	929,000	529,000	380,000	342,000	462,000
total research revenue																																																																															2,104,000	2,057,000	3,702,000	5,608,000	6,350,000	6,774,000	8,868,000
income taxes																																																																																			42,000	125,000	125,000

We provide you with 20 years income statements for Myriad Genetics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Myriad Genetics stock. Explore the full financial landscape of Myriad Genetics stock with our expertly curated income statements.

The information provided in this report about Myriad Genetics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.